GOP won't offer input on nominees to controversial ObamaCare panelBy Sam Baker - 05/09/13 10:00 AM ETCongressional Republicans are refusing to recommend members for a controversial panel designed to slow the growth of Medicare spending.The panel was created by President Obama's healthcare law and structured to ensure some level of bipartisan input. But House Speaker John Boehner (R-Ohio) and Senate Majority Leader Mitch McConnell (R-Ky.) said Thursday they will not recommend anyone to serve on the board.They say the panel — known as the Independent Payment Advisory Board (IPAB) — ought to be repealed. It's one of the controversial sections of the law Republicans have singled out for repeal votes."We believe Congress should repeal IPAB, just as we believe we ought to repeal the entire healthcare law … We hope establishing this board never becomes a reality, which is why full repeal of the Affordable Care Act remains our goal," Boehner and McConnell wrote in a letter to Obama.The IPAB is a 15-member panel of healthcare experts. The healthcare law gives Boehner and McConnell three recommendations each, and another three to each of their Democratic counterparts. All 15 board members would have to be confirmed by the Senate.Once in place, the IPAB would make targeted cuts in Medicare's payments to doctors and other providers if the program's overall spending grows faster than a certain rate. The board is not allowed to alter Medicare benefits or "ration" care."These reduced payments will force providers to stop seeing Medicare patients, the same way an increased number of doctors have stopped taking Medicaid patients. This will lead to access problems, waiting lists and denied care for seniors," Boehner and McConnell wrote.Obama has not yet nominated anyone to the IPAB.The panel was supposed to come into existence in 2014, but Medicare spending has not grown slowly enough that the IPAB would not be triggered next year.
This is pretty typical of the reporting on the IPAB cariadhttp://thehill.com/blogs/healthwatch/health-reform-implementation/298733-gop-wont-offer-input-on-nominees-to-controversial-obamacare-panelQuoteGOP won't offer input on nominees to controversial ObamaCare panelBy Sam Baker - 05/09/13 10:00 AM ETCongressional Republicans are refusing to recommend members for a controversial panel designed to slow the growth of Medicare spending.The panel was created by President Obama's healthcare law and structured to ensure some level of bipartisan input. But House Speaker John Boehner (R-Ohio) and Senate Majority Leader Mitch McConnell (R-Ky.) said Thursday they will not recommend anyone to serve on the board.They say the panel — known as the Independent Payment Advisory Board (IPAB) — ought to be repealed. It's one of the controversial sections of the law Republicans have singled out for repeal votes."We believe Congress should repeal IPAB, just as we believe we ought to repeal the entire healthcare law … We hope establishing this board never becomes a reality, which is why full repeal of the Affordable Care Act remains our goal," Boehner and McConnell wrote in a letter to Obama.The IPAB is a 15-member panel of healthcare experts. The healthcare law gives Boehner and McConnell three recommendations each, and another three to each of their Democratic counterparts. All 15 board members would have to be confirmed by the Senate.Once in place, the IPAB would make targeted cuts in Medicare's payments to doctors and other providers if the program's overall spending grows faster than a certain rate. The board is not allowed to alter Medicare benefits or "ration" care."These reduced payments will force providers to stop seeing Medicare patients, the same way an increased number of doctors have stopped taking Medicaid patients. This will lead to access problems, waiting lists and denied care for seniors," Boehner and McConnell wrote.Obama has not yet nominated anyone to the IPAB.The panel was supposed to come into existence in 2014, but Medicare spending has not grown slowly enough that the IPAB would not be triggered next year.The only actual criticism from Bohner/McConnell is that "These reduced payments will force providers to stop seeing Medicare patients, the same way an increased number of doctors have stopped taking Medicaid patients. This will lead to access problems, waiting lists and denied care for seniors" which is saying if Medicare paid Medicaid rates it would be a problem but Medicaid, where it is a problem, pays 80% of the Medicare allowed rate, while the IPAB would, at some point in the future (the most recent CBO data says at some point over ten years in the future) propose to decrease the rate of Medicare reimbursement growth for particular services. The dynamic marginally affecting Medicaid isn't possible due to any action by the IPAB.I have never seen any engagement on the issue from the IPAB's political opponents, that acknowledges the current system is fully captured by medical doctors in specialty practices. There is actually a lot of push back in health policy circles against Medicare for relying upon the RUC as the primary source of recommendations for determining physician work values, accepting over 90 percent of the committee’s recommendations, but you never hear about this in the context of the IPAB. For one the Society of General Internal Medicine has stood for diminishing the RUC's influence but even so many internists are not aware of the AMA's committee's corrosive role in setting Medicare reimbursement.The IPAB is the first alternative to be signed into law (Congress McDermott proposed legislation in 2011 that went nowhere) and now with cynical disregard for fixing the problem the IPAB is being demonized by those playing political games, chief among them Bohner and McConnell.
Reimbursement drives practice - the framework the RUC enables is a zero sum game. If the committee thinks docs should be paid more for providing an endoscopic ultrasound some other procedure has to be paid less. The problem with the framework is that it is based on how hard the procedure is to provide not on how effective it is, the RUC doesn't value a doctor who keeps their patient from getting sick in the first place. This is the rotten heart of our healthcare reimbursement and why a functioning IPAB is important.I just found this website today http://www.replacetheruc.org/ it is an eye opener.
I think I addressed your concerns in my initial post - let me know where my post comes up short.This idea about QALY doesn't come into play in the least. PCORI's job is to look at procedures, not who receives them, just as the RUC does in fact. For instance, in dialysis the obvious one is catheter/graft/fistula. Which procedure should be reimbursed more? Should placing a catheter be more lucrative than placing a graft? Should placing a graft be more lucrative than placing a fistula? Currently reimbursement rewards docs who place and maintain a catheter to a greater degree than docs who place a successful fistula. That's the RUC way, but it is far from ideal. I can imagine a reimbursement policy that rewards a successful fistula placement. I would endorse a payment policy that continues to give some nominal sum to the surgeon that placed my fistula 23 years ago (this week). The RUC would not ever consider such a scheme while PCORI has the latitude to offer such a scheme as a solution, as a way to improve patient's well being and keep down Medicare's costs by avoiding hospitalizations.Something like hemodiafiltration is another example. If hemodiafiltration improved clinical outcomes and decreased the disease/treatment burden of CKD5 than PCORI could make providing HDF more lucrative than providing conventional HD. RUC wouldn't distinguish between the procedures since they require the same physician effort. These examples are from just one small corner of medical practice that we are familiar with but I think there are examples from just about every field of medicine. I think it is to dialyzors clear advantage to support PCORI and stand opposed to the RUC.
Quote from: Bill Peckham on May 13, 2013, 08:36:10 AMI think I addressed your concerns in my initial post - let me know where my post comes up short.This idea about QALY doesn't come into play in the least. PCORI's job is to look at procedures, not who receives them, just as the RUC does in fact. For instance, in dialysis the obvious one is catheter/graft/fistula. Which procedure should be reimbursed more? Should placing a catheter be more lucrative than placing a graft? Should placing a graft be more lucrative than placing a fistula? Currently reimbursement rewards docs who place and maintain a catheter to a greater degree than docs who place a successful fistula. That's the RUC way, but it is far from ideal. I can imagine a reimbursement policy that rewards a successful fistula placement. I would endorse a payment policy that continues to give some nominal sum to the surgeon that placed my fistula 23 years ago (this week). The RUC would not ever consider such a scheme while PCORI has the latitude to offer such a scheme as a solution, as a way to improve patient's well being and keep down Medicare's costs by avoiding hospitalizations.Something like hemodiafiltration is another example. If hemodiafiltration improved clinical outcomes and decreased the disease/treatment burden of CKD5 than PCORI could make providing HDF more lucrative than providing conventional HD. RUC wouldn't distinguish between the procedures since they require the same physician effort. These examples are from just one small corner of medical practice that we are familiar with but I think there are examples from just about every field of medicine. I think it is to dialyzors clear advantage to support PCORI and stand opposed to the RUC.Well, first of all, PCORI only does the research as you know, it is not a decision making entity. That will be the IPAB. However, you may be a bit too generous in the findings of PCORI. For instance, to date daily dialysis, or quotidian dialysis is still viewed as "controversial" especially be the man who is the CER rep, or whatever his actual title is for dialysis, Glen Chertow. If it were up to Chertow to recommend paying for quotidian dialysis, all his writing would suggest he would state it has not been proven better than conventional in-center hemodialysis. That is the current state of belief by academic nephrologists. In such a system, although I have no doubt that Chertow is wrong, how would you petition the government to proceed? As you have admitted, all of our advocacy to date has essentially failed to change the system. Why would we trust CER headed by Chertow and the IPAB?
Quote from: Hemodoc on May 13, 2013, 09:40:40 AMQuote from: Bill Peckham on May 13, 2013, 08:36:10 AMI think I addressed your concerns in my initial post - let me know where my post comes up short.This idea about QALY doesn't come into play in the least. PCORI's job is to look at procedures, not who receives them, just as the RUC does in fact. For instance, in dialysis the obvious one is catheter/graft/fistula. Which procedure should be reimbursed more? Should placing a catheter be more lucrative than placing a graft? Should placing a graft be more lucrative than placing a fistula? Currently reimbursement rewards docs who place and maintain a catheter to a greater degree than docs who place a successful fistula. That's the RUC way, but it is far from ideal. I can imagine a reimbursement policy that rewards a successful fistula placement. I would endorse a payment policy that continues to give some nominal sum to the surgeon that placed my fistula 23 years ago (this week). The RUC would not ever consider such a scheme while PCORI has the latitude to offer such a scheme as a solution, as a way to improve patient's well being and keep down Medicare's costs by avoiding hospitalizations.Something like hemodiafiltration is another example. If hemodiafiltration improved clinical outcomes and decreased the disease/treatment burden of CKD5 than PCORI could make providing HDF more lucrative than providing conventional HD. RUC wouldn't distinguish between the procedures since they require the same physician effort. These examples are from just one small corner of medical practice that we are familiar with but I think there are examples from just about every field of medicine. I think it is to dialyzors clear advantage to support PCORI and stand opposed to the RUC.Well, first of all, PCORI only does the research as you know, it is not a decision making entity. That will be the IPAB. However, you may be a bit too generous in the findings of PCORI. For instance, to date daily dialysis, or quotidian dialysis is still viewed as "controversial" especially be the man who is the CER rep, or whatever his actual title is for dialysis, Glen Chertow. If it were up to Chertow to recommend paying for quotidian dialysis, all his writing would suggest he would state it has not been proven better than conventional in-center hemodialysis. That is the current state of belief by academic nephrologists. In such a system, although I have no doubt that Chertow is wrong, how would you petition the government to proceed? As you have admitted, all of our advocacy to date has essentially failed to change the system. Why would we trust CER headed by Chertow and the IPAB?When I wrote PCORI I meant IPAB - should have waited for coffee. Chertow is exactly the sort of person who meets in secret on the RUC, again IPAB has to be judged against what we have now. If everything we have done has not changed the system then maybe we should try a new system.
The IPAB doesn't simply endorse the view of a physician, while apparently the RUC does but I will say the data on more frequent dialysis is still being developed. As an HHD advocate I have no fear of anything that mines and or develops data because I believe in the efficacy of HHD. But what I think, my N=1 does not count for much in the real world. We are seeing a tremendous push back against the buttonhole because the data has raised concerns. I say that as an example of something I believe in as beneficial not being fully, unequivocally supported in the data. People of Dr Chertow's generation were snake bit by EPO and I think their caution is a reflection of their professional experience. If HHD ever generates enough data points to be convincingly compared to conventional HD then I am confident HHD's superiority will shine through, if it doesn't then reality will have to be accommodated. However, right now more frequent HHD is being reimbursed at a level never dreamed of by more frequent advocates and yet we see a failure to thrive. I think it is well past time to move on from reimbursement to other factors not related to IPAB's work. I think my example of the access question is more relevant and pressing for a greater number of people and has more important potential impact. I am still interested in your take on the access issue and how it should be addressed if you see a problem.And one other thing to consider when comparing IPAB with the RUC is that IPAB members will receive executive level federal compensation, they are not allowed to hold other positions. Compared to the RUC where practicing specialists work on policies that directly impact their livelihoods.